Navigation Links
Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Date:7/23/2008

_new">(http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the NASDAQ Listing Qualifications Panel will not grant the Company a sufficient amount of time to fully implement its plan to regain compliance. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008. The company cautions investors not to place undu
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LA JOLLA, Calif. , July 30, 2014 /PRNewswire/ ... RGLS ), a biopharmaceutical company leading the discovery and ... it will report financial results and highlights for the ... 2014, after the U.S. financial markets close. ... on Wednesday, August 6, 2014, at 5:00 pm Eastern ...
(Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... The National Science Foundation,(NSF) has awarded Loma ... of $593,978 to lead a consortium in developing ... universities. Barry L. Taylor, Ph.D., Professor of Microbiology,and ... Affairs,will lead the project with Rohit Shukla, CEO ...
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX:ONY) announced ... studies of PX-12 and preclinical studies of,PX-866 will ... American Association,for Cancer Research (AACR) in San Diego ... a Phase 1 clinical trial of PX-478,in patients ...
... Biopure,Corporation (Nasdaq: BPUR ) announced today that ... its independent auditor., The audit committee of ... review of audit firms that had expertise with ... in Boston, Massachusetts, Vitale, Caturano & Company, Ltd. ...
Cached Biology Technology:Loma Linda University Partners With Larta Institute for Technology Marketing Program 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 3
(Date:7/30/2014)... Lewis Carroll,s Through the Looking Glass, collaborators from ... Singapore improved a 35-year-old ecology model to better ... of years. , The new model, called a ... Queen Effect," an evolutionary hypothesis introduced by Lee ... organisms must constantly increase their fitness (or ability ...
(Date:7/30/2014)... A deep-sea octopus protected and tended her eggs until ... published July 30, 2014 in the open-access journal ... Aquarium Research Institute and colleagues. , Octopuses typically have ... females protect and take care of their fertilized eggs ... eggs for 1 to 3 months, but little is ...
(Date:7/30/2014)... announced today that David L. Kaplan, Ph.D., will head ... Engineering as editor-in-chief. With the first issue slated ... feature high-quality research in the rapidly burgeoning field of ... that interact with living or biological systems. , "This ... growth in the field of biomaterials over the past ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... U.S. Department of,Homeland Security (DHS) announced today ... international visitors arriving at Boston,Logan International Airport ... department,s,upgrade from two- to 10-fingerprint collection to ... accurately and efficiently,establishing and verifying visitors, identities., ...
... About the Ocean Sciences Meeting News Media Registration ... 4 February 2008 Abstracts and Schedule Available Online Who,s ... This years meeting will offer a wealth of new ... it is found, from mountain peaks to deep ocean ...
... bring a combination of individual scientific skills, expertise ... these offer the opportunity to build a highly ... address the urgent need for bringing new antibiotic ... antibiotics and other antimicrobial agents have saved millions ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at Boston Logan International Airport 2Media advisory -- 2008 Ocean Sciences Meeting 2Media advisory -- 2008 Ocean Sciences Meeting 3Media advisory -- 2008 Ocean Sciences Meeting 4Unique fungal collection could hold key to future antibiotics 2Unique fungal collection could hold key to future antibiotics 3
... is an inhibitor of ... concentration of inhibitor required ... must be determined empirically ... micromolar inhibitor is sufficient ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: